Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study - PubMed (original) (raw)
. 2011 Mar 22;76(12):1085-90.
doi: 10.1212/WNL.0b013e318212015e. Epub 2011 Feb 16.
Affiliations
- PMID: 21325653
- DOI: 10.1212/WNL.0b013e318212015e
Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study
J Koivunen et al. Neurology. 2011.
Abstract
Background: Patients with amnestic mild cognitive impairment (MCI) have greater risk of conversion to Alzheimer disease (AD). Increased brain amyloid burden in AD and MCI has been demonstrated with PET using [(11)C] Pittsburgh compound B (PiB) as a tracer.
Objective: To evaluate change in β-amyloid deposition in with MCI during 2-year follow-up.
Methods: Patients with MCI and controls were studied with [(11)C] PiB PET, MRI, and neuropsychometry at baseline and these investigations were repeated in patients with MCI after follow-up.
Results: Those patients with MCI converting to AD during follow-up had greater [(11)C] PiB retention in the posterior cingulate (p=0.020), in the lateral frontal cortex (p=0.006), in the temporal cortex (p=0.022), in the putamen (p=0.041), and in the caudate nucleus (p=0.025) as compared to nonconverters. In converters, there was no significant change in [(11)C] PiB uptake, whereas an increase was seen as compared to baseline in nonconverters in the anterior and posterior cingulate, temporal and parietal cortices, and putamen. Hippocampal atrophy was greater in converters at baseline than in nonconverters, but increased significantly in both groups during follow-up.
Conclusions: Hippocampal atrophy and amyloid deposition seem to dissociate during the evolution of MCI, the atrophy increasing clearly and [(11)C] PiB retention changing modestly when conversion to AD occurs. Longer follow-up is needed to determine whether nonconverters would convert to AD later, which would suggest accelerated [(11)C] PiB retention preceding clinical conversion.
© 2011 by AAN Enterprises, Inc.
Similar articles
- Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.
Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ. Okello A, et al. Neurology. 2009 Sep 8;73(10):754-60. doi: 10.1212/WNL.0b013e3181b23564. Epub 2009 Jul 8. Neurology. 2009. PMID: 19587325 Free PMC article. - PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO. Kemppainen NM, et al. Neurology. 2007 May 8;68(19):1603-6. doi: 10.1212/01.wnl.0000260969.94695.56. Neurology. 2007. PMID: 17485647 - Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
Koivunen J, Karrasch M, Scheinin NM, Aalto S, Vahlberg T, Någren K, Helin S, Viitanen M, Rinne JO. Koivunen J, et al. Dement Geriatr Cogn Disord. 2012;34(1):31-7. doi: 10.1159/000341580. Epub 2012 Aug 3. Dement Geriatr Cogn Disord. 2012. PMID: 22868352 - PET imaging of brain amyloid in dementia: a review.
Quigley H, Colloby SJ, O'Brien JT. Quigley H, et al. Int J Geriatr Psychiatry. 2011 Oct;26(10):991-9. doi: 10.1002/gps.2640. Epub 2010 Dec 28. Int J Geriatr Psychiatry. 2011. PMID: 21905095 Review. - Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease.
Chételat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of Ageing Research Group. Chételat G, et al. Neurodegener Dis. 2012;10(1-4):141-4. doi: 10.1159/000334295. Epub 2012 Feb 1. Neurodegener Dis. 2012. PMID: 22301812 Review.
Cited by
- Cortico-limbic volume abnormalities in late life depression are distinct from β amyloid and white matter pathologies.
Mackin RS, Rhodes E, Kassel M, Kryza-Lacombe M, Burns E, Bickford D, Morin R, Tosun D, Landau S, Butters MA, Aisen P, Raman R, Saykin AJ, Toga A, Koeppe R, Jack C, Weiner MW, Nelson C, Insel PS. Mackin RS, et al. Mol Psychiatry. 2024 Nov 7. doi: 10.1038/s41380-024-02677-4. Online ahead of print. Mol Psychiatry. 2024. PMID: 39511448 - New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map.
Okuyama C, Higashi T, Ishizu K, Oishi N, Kusano K, Ito M, Kagawa S, Okina T, Suzuki N, Hasegawa H, Nagahama Y, Watanabe H, Ono M, Yamauchi H. Okuyama C, et al. Ann Nucl Med. 2024 Sep;38(9):763-773. doi: 10.1007/s12149-024-01956-y. Epub 2024 Jun 22. Ann Nucl Med. 2024. PMID: 38907835 Free PMC article. - Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.
Duff K, Hammers DB, Koppelmans V, King JB, Hoffman JM. Duff K, et al. J Alzheimers Dis. 2024;99(1):321-332. doi: 10.3233/JAD-231392. J Alzheimers Dis. 2024. PMID: 38669544 - Multi-domain cognition dysfunction accompanies frontoparietal and temporal amyloid accumulation in the elderly.
Wang D, Xu K, Dang M, Sang F, Chen K, Zhang Z, Li X. Wang D, et al. Cereb Cortex. 2023 Nov 27;33(23):11329-11338. doi: 10.1093/cercor/bhad369. Cereb Cortex. 2023. PMID: 37859548 Free PMC article. - Advances in diagnosing mild cognitive impairment and Alzheimer's disease using 11C-PIB- PET/CT and common neuropsychological tests.
Zhao Q, Du X, Chen W, Zhang T, Xu Z. Zhao Q, et al. Front Neurosci. 2023 Jul 10;17:1216215. doi: 10.3389/fnins.2023.1216215. eCollection 2023. Front Neurosci. 2023. PMID: 37492405 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources